Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04471909 · ClinicalTrials.gov registry record · NA

NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

A NA study of Aortic Aneurysm and Aortic Dissection, sponsored by Endospan.

Recruiting
Registry status
NA
Development phase
110
Enrollment target
20
Study locations

NCT04471909: Recruiting NA study of Aortic Aneurysm and Aortic Dissection, sponsored by Endospan.

NCT04471909 is a NA study of Aortic Aneurysm and Aortic Dissection that is actively recruiting participants, run by Endospan. The registered enrollment target is 110 participants, below the 632-participant average among 14 other Aortic Aneurysm trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04471909, a NA study of Aortic Aneurysm and Aortic Dissection, is actively recruiting participants, sponsored by Endospan.

RECRUITING
Registry status
NA
Development phase
110 participants
Enrollment target
20
Study locations

Study Summary

Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.

Primary Outcome

* Failure to accurately deliver, track and deploy all required endovascular device components at the intended implantation site and failure to retrieve the device delivery systems without the need for unplanned additional procedures * Device occlusion * Failed exclusion of primary entry tear * Additional unanticipated surgical or interventional procedure related to the device or procedure, to prevent life-threatening or permanent disabling event.

Interventions

  • DEVICE NEXUS Aortic Stent Graft System

Study Locations (20)

California

  • University of California San Diego Medical Center - La Jolla
  • UC Davis Health - Sacramento
  • Stanford University School of Medicine - Stanford

North Carolina

  • University of North Carolina - Chapel Hill
  • Atrium Health - Charlotte
  • Duke University Medical Center - Durham

New York

  • The Mount Sinai Medical Center - New York
  • Northwell Health Lenox Hill Hospital - New York

Alabama

  • University of Alabama Birmingham - Birmingham

Colorado

  • University of Colorado - Aurora

Connecticut

  • Hartford Hospital - Hartford

District of Columbia

  • MedStar Washington Hospital - Washington D.C.

Florida

  • Advent Health Orlando - Orlando

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2020-10-20
Est. Completion 2029-10
Phase NA
Endospan

1 total trials

What NCT04471909 shows while recruiting

NCT04471909 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 632-participant average among 14 other Aortic Aneurysm trials with a reported enrollment target (83% lower).

The record links to 4 conditions, with Aortic Aneurysm appearing as the primary indexed condition, and to 1 intervention - of which NEXUS Aortic Stent Graft System is the first listed.

NCT04471909 names 20 study sites across 15 states, led by California, North Carolina, New York.

Frequently Asked Questions

What is clinical trial NCT04471909 about?

NCT04471909 is a clinical study titled "NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness". Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with ...

What is the current status of trial NCT04471909?

This trial is currently recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2020-10-20. Estimated completion is 2029-10.

What conditions does trial NCT04471909 study?

This clinical trial studies the following conditions: Aortic Aneurysm, Aortic Dissection, Intramural Hematoma, Penetrating Aortic Ulcer.

What interventions are being tested in trial NCT04471909?

The interventions under investigation include: NEXUS Aortic Stent Graft System (DEVICE).

Who is sponsoring clinical trial NCT04471909?

This trial is sponsored by Endospan, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04471909 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Aneurysm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04471909's enrollment target sits among peer trials

110 8th of 14 higher than 7 of 14 other Aortic Aneurysm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aortic Aneurysm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04471909, the US trial registry maintained by the National Library of Medicine. NCT04471909 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.